Bristol-Myers Squibb (BMS) and Moffitt Cancer Center joined forces today as part of BMS’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM program is a ...
No audio available for this content. It should be noted that many of these large GPS on BM residuals could be due to an invalid NAVD 88 published height because the bench mark moved since the last ...
UCLA is the latest institution to join Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) research program in the U.S. Through the I-O RPM program, BMS and the David Geffen ...
Bristol Myers Squibb is paying nearly half a billion in near-term and upfronts to licence Dragonfly Therapeutics’ interleukin-12 (IL-12) immunotherapy program. This program is the early-stage ...
Just days ago, Bristol Myers Squibb was touting new data for the targeted heart drug mavacamten. Now, the Big Pharma has announced that the FDA has extended the decision date for the drug, which was ...
No audio available for this content. My last column described how the U.S. National Geodetic Survey (NGS) used the detailed analysis of the latest GPS on Bench Marks dataset to: generate a prototype ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results